 The purpose of this study is to compare the safety and efficacy of different induction agents alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in renal transplant recipients treated with tacrolimus, mycophenolate mofetil MMF and a rapid steroid withdrawal. 